These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16176420)

  • 21. Ten-year follow-up of a prospective, randomized trial of BT563/bb10 versus anti-thymocyte globulin as induction therapy after heart transplantation.
    Bonaros N; Dunkler D; Kocher A; Imhof M; Grimm M; Zuckermann A; Wolner E; Laufer G
    J Heart Lung Transplant; 2006 Sep; 25(9):1154-63. PubMed ID: 16962480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ATG induction therapy: long-term effects on Th1 but not on Th2 responses.
    Weimer R; Staak A; Süsal C; Streller S; Yildiz S; Pelzl S; Renner F; Dietrich H; Daniel V; Rainer L; Kamali-Ernst S; Ernst W; Padberg W; Opelz G
    Transpl Int; 2005 Feb; 18(2):226-36. PubMed ID: 15691277
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?
    Birkeland SA; Hamilton-Dutoit S
    Transplantation; 2003 Sep; 76(6):984-8. PubMed ID: 14508366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders.
    Kinch A; Baecklund E; Molin D; Pauksens K; Sundström C; Tufveson G; Enblad G
    Acta Oncol; 2021 Jun; 60(6):771-778. PubMed ID: 33793378
    [No Abstract]   [Full Text] [Related]  

  • 25. Post-transplant lymphoproliferative disorder: no relationship to recombinant human growth hormone use in Australian and New Zealand pediatric kidney transplant recipients.
    Longmore DK; Conwell LS; Burke JR; McDonald SP; McTaggart SJ
    Pediatr Transplant; 2013 Dec; 17(8):731-6. PubMed ID: 24164826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients.
    Lee TC; Savoldo B; Barshes NR; Rooney CM; Heslop HE; Gee AP; Caldwell Y; Scott JD; Goss JA
    Clin Transplant; 2006; 20(3):389-93. PubMed ID: 16824159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
    Pascual J
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased beta 2-microglobulin (B2M) is useful in the detection of post-transplant lymphoproliferative disease (PTLD).
    Sasaki TM; Pirsch JD; D'Alessandro AM; Knechtle SJ; Kalayoglu M; Hafez GR; Sollinger HW
    Clin Transplant; 1997 Feb; 11(1):29-33. PubMed ID: 9067691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-transplant lymphoproliferative disease in pediatric lung transplant recipients: recent advances in monitoring.
    Elidemir O; Kancherla BS; Schecter MG; McKenzie ED; Morales DL; Heinle JS; Mallory GB
    Pediatr Transplant; 2009 Aug; 13(5):606-10. PubMed ID: 19017289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute.
    Hou HA; Yao M; Tang JL; Chen YK; Ko BS; Huang SY; Tien HF; Chang HH; Lu MY; Lin TT; Lin KH; Hsiao CH; Lin CW; Chen YC
    Bone Marrow Transplant; 2009 Feb; 43(4):315-21. PubMed ID: 18836488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case-control study of risk factors for the development of post-transplant lymphoproliferative disease in a pediatric heart transplant cohort.
    Katz BZ; Pahl E; Crawford SE; Kostyk MC; Rodgers S; Seshadri R; Proytcheva M; Pophal S
    Pediatr Transplant; 2007 Feb; 11(1):58-65. PubMed ID: 17239124
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abdominal involvement in pediatric heart and lung transplant recipients with posttransplant lymphoproliferative disease increases the risk of mortality.
    Tai CC; Curtis JL; Szmuszkovicz JR; Horn MV; Ford HR; Woo MS; Wang KS
    J Pediatr Surg; 2008 Dec; 43(12):2174-7. PubMed ID: 19040929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction regimens and post-transplantation lymphoproliferative disorder after pediatric intestinal transplantation: Single-center experience.
    Devine K; Ranganathan S; Mazariegos G; Bond G; Soltys K; Ganoza A; Sun Q; Sindhi R
    Pediatr Transplant; 2020 Aug; 24(5):e13723. PubMed ID: 32424963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term follow-up of kidney transplant patients with posttransplant lymphoproliferative disorder: duration of posttransplant lymphoproliferative disorder-induced operational graft tolerance, interleukin-18 course, and results of retransplantation.
    Birkeland SA; Hamilton-Dutoit S; Bendtzen K
    Transplantation; 2003 Jul; 76(1):153-8. PubMed ID: 12865802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Posttransplantation lymphoproliferative disorder--the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus.
    Koch DG; Christiansen L; Lazarchick J; Stuart R; Willner IR; Reuben A
    Liver Transpl; 2007 Jun; 13(6):904-12. PubMed ID: 17539010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-transplantation lymphoproliferative disorder after kidney transplantation: report of a nationwide French registry and the development of a new prognostic score.
    Caillard S; Porcher R; Provot F; Dantal J; Choquet S; Durrbach A; Morelon E; Moal V; Janbon B; Alamartine E; Pouteil Noble C; Morel D; Kamar N; Buchler M; Mamzer MF; Peraldi MN; Hiesse C; Renoult E; Toupance O; Rerolle JP; Delmas S; Lang P; Lebranchu Y; Heng AE; Rebibou JM; Mousson C; Glotz D; Rivalan J; Thierry A; Etienne I; Moal MC; Albano L; Subra JF; Ouali N; Westeel PF; Delahousse M; Genin R; Hurault de Ligny B; Moulin B
    J Clin Oncol; 2013 Apr; 31(10):1302-9. PubMed ID: 23423742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study.
    Buadi FK; Heyman MR; Gocke CD; Rapoport AP; Hakimian R; Bartlett ST; Sarkodee-Adoo C
    Am J Hematol; 2007 Mar; 82(3):208-14. PubMed ID: 17022049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Posttransplant lymphoproliferative disorder after umbilical cord blood transplantation in children.
    Gong JZ; Bayerl MG; Sandhaus LM; Sebastian S; Rehder CW; Routbort M; Lagoo AS; Szabolcs P; Chiu J; Comito M; Buckley PJ
    Am J Surg Pathol; 2006 Mar; 30(3):328-36. PubMed ID: 16538052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Slc11a1 (formerly Nramp1) polymorphisms and susceptibility to post-transplant lymphoproliferative disease following pediatric liver transplantation.
    Barshes NR; Lee TR; Goss JA; Goodpastor SE; Huls MH; Rooney CM; Karpen SJ; Wyllie S
    Transpl Infect Dis; 2006 Jun; 8(2):108-12. PubMed ID: 16734634
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship between rabbit anti-thymocyte globulin and development of PTLD and its aggressive form in renal transplant population.
    Ali H; Soliman K; Daoud A; Elsayed I; Fülöp T; Sharma A; Halawa A
    Ren Fail; 2020 Nov; 42(1):489-494. PubMed ID: 32423337
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.